Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 98.15% is in line with its 5-year average of 100.00%, near the high end of its 5-year range (92.95%–100.00%).
0.45% below its 12-month average of 98.59%.
Reported quarterly gross margin; no daily interpolation. Q3 FY2026 (2026-06-30): 100.00%.
GROSS MARGIN
98.15%
GROSS MARGIN AVG TTM
98.59%
GROSS MARGIN AVG 3Y
100.00%
GROSS MARGIN AVG 5Y
100.00%
GROSS MARGIN AVG 10Y
100.00%
GROSS MARGIN AVG 15Y
100.00%
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-0.45%
CURRENT VS 3Y AVG
-1.85%
CURRENT VS 5Y AVG
-1.85%
CURRENT VS 10Y AVG
-1.85%
CURRENT VS 15Y AVG
-1.85%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
47.19%
median of 508 covered companies
CURRENT VS SECTOR MEDIAN
+108.01%
vs the sector median at left
Enanta Pharmaceuticals, Inc.
Market Cap
$368.13M
Gross Margin
98.15%
TTM Avg
98.59%
3Y Avg
100.00%
5Y Avg
100.00%
Market Cap
$368.66M
Gross Margin
99.87%
TTM Avg
100.00%
3Y Avg
100.00%
5Y Avg
83.33%
Market Cap
$369.60M
Gross Margin
93.73%
TTM Avg
92.44%
3Y Avg
93.34%
5Y Avg
78.89%
Market Cap
$379.26M
Gross Margin
25.47%
TTM Avg
27.02%
3Y Avg
15.55%
5Y Avg
5.84%
Market Cap
$348.59M
Gross Margin
0.00%
TTM Avg
50.00%
3Y Avg
75.00%
5Y Avg
66.67%
Market Cap
$387.87M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
25.00%
5Y Avg
40.00%
Market Cap
$347.88M
Gross Margin
62.61%
TTM Avg
61.15%
3Y Avg
61.24%
5Y Avg
64.05%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Enanta Pharmaceuticals, Inc. (ENTA) | $368.13M | 98.15% | 98.59% | 100.00% | 100.00% |
| Opus Genetics, Inc. (IRD)vs › | $368.66M | 99.87% | 100.00% | 100.00% | 83.33% |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $369.60M | 93.73% | 92.44% | 93.34% | 78.89% |
| Canopy Growth Corporation (CGC)vs › | $379.26M | 25.47% | 27.02% | 15.55% | 5.84% |
| Agenus Inc. (AGEN)vs › | $353.54M | 29.63% | -10.58% | -43.61% | -33.41% |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $348.59M | 0.00% | 50.00% | 75.00% | 66.67% |
| Embecta Corp. (EMBC)vs › | $348.55M | 59.89% | 63.90% | 65.83% | 67.05% |
| Kyverna Therapeutics, Inc. (KYTX)vs › | $387.87M | 0.00% | 0.00% | 25.00% | 40.00% |
| ClearPoint Neuro, Inc. (CLPT)vs › | $347.88M | 62.61% | 61.15% | 61.24% | 64.05% |
| Cabaletta Bio, Inc. (CABA)vs › | $342.42M | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
98.2%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 100.00% |
| 2026-03-31 | 92.95% |
| 2025-12-31 | 100.00% |
| 2025-09-30 | 100.00% |
| 2025-06-30 | 100.00% |
| 2025-03-31 | 100.00% |
| 2024-12-31 | 100.00% |
| 2024-09-30 | 100.00% |
| 2024-06-30 | 100.00% |
| 2024-03-31 | 100.00% |
| 2023-12-31 | 100.00% |
| 2023-09-30 | 100.00% |
| 2023-06-30 | 100.00% |
| 2023-03-31 | 96.97% |
| 2022-12-31 | 97.83% |
| 2022-09-30 | 96.78% |
| 2022-06-30 | 96.32% |
| 2022-03-31 | 100.00% |
| 2021-12-31 | 100.00% |
| 2021-09-30 | 100.00% |
| 2021-06-30 | 100.00% |
| 2021-03-31 | 100.00% |
| 2020-12-31 | 100.00% |
| 2020-09-30 | 100.00% |
| 2020-06-30 | 100.00% |
| 2020-03-31 | 100.00% |
| 2019-12-31 | 100.00% |
| 2019-09-30 | 100.00% |
| 2019-06-30 | 100.00% |
| 2019-03-31 | 100.00% |
| 2018-12-31 | 100.00% |
| 2018-09-30 | 100.00% |
| 2018-06-30 | 100.00% |
| 2018-03-31 | 100.00% |
| 2017-12-31 | 100.00% |
| 2017-09-30 | 100.00% |
| 2017-06-30 | 100.00% |
| 2017-03-31 | 100.00% |
| 2016-12-31 | 100.00% |
| 2016-09-30 | 100.00% |
| 2016-06-30 | 100.00% |
| 2016-03-31 | 100.00% |
| 2015-12-31 | 100.00% |
| 2015-09-30 | 100.00% |
| 2015-06-30 | 100.00% |
| 2015-03-31 | 100.00% |
| 2014-12-31 | 100.00% |
| 2014-09-30 | 100.00% |
| 2014-06-30 | 100.00% |
| 2014-03-31 | 100.00% |
| 2013-12-31 | 100.00% |
| 2013-09-30 | 100.00% |
| 2013-06-30 | 100.00% |
| 2013-03-31 | 100.00% |
| 2012-12-31 | 100.00% |
| 2012-09-30 | 100.00% |
| 2012-06-30 | 100.00% |
| 2012-03-31 | 100.00% |
| 2011-12-31 | 100.00% |
| 2011-09-30 | 0.00% |
